A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps
← catalyst calendarNCT05866614 · readout ≤ 224 d
Sponsored by Celltrion (industry) · 068270.KS — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
881actual
Sites
1
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-13 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Psoriasis
Interventions
- Drug: Remsima IV
- Drug: Remsima SC
Primary outcome
what the primary-completion date above is the date OFevaluation of adverse events of special interest (AESI)
measured through study completion, an average of 2 years
Permalink · 068270.KS's whole pipeline · Catalyst calendar · Every registered study · What changed